Peptide therapy TikTok claims: separating hype from human data

What did @.dr.sim.bhatti actually say?

Dr. Bhatti is not anti-peptide across the board. His specific concern is "chronic use" of TB-500, TB4, and BPC-157 without what he calls "appropriate context," citing cancer risk from a mechanistic standpoint. He also criticizes the affiliate-code culture around peptide promotion.

This is actually a more nuanced position than most of his critics give him credit for. He is not claiming these peptides are universally dangerous or that no one should ever use them. He is arguing that the risk conversation is being systematically drowned out by people with financial incentives to sell product. That framing is worth taking seriously before picking apart the science underneath it. The distinction between short-term therapeutic use and chronic optimization use is real in pharmacology, even if he does not fully elaborate it here.

Does the science back this up?

On the mechanistic cancer concern, he is pointing at something real but presenting it as more settled than it actually is. The evidence is preclinical and context-dependent, not a clean warning label.

BPC-157 and TB-500 (a synthetic fragment of thymosin beta-4) both influence angiogenesis and cell migration pathways. BPC-157 activates the VEGF pathway and interacts with growth hormone receptors. Thymosin beta-4 promotes actin polymerization and has been shown to upregulate certain oncogenic signals in cell culture. A 2021 review by Seiwerth et al. in Current Pharmaceutical Design noted BPC-157's pro-angiogenic effects and flagged the theoretical concern in tumor microenvironments. However, the same review also pointed to cytoprotective and anti-inflammatory findings in rodent models. The honest read is that no controlled human trial has demonstrated that BPC-157 or TB-500 causes or accelerates cancer in healthy people. The concern is theoretical and preclinical, not clinical evidence of harm. Framing it as a "very real risk" without that caveat is an overstatement.

What did they get wrong (or right)?

He gets the affiliate-code critique exactly right. He gets the preclinical signal right. Where he overshoots is in the certainty of the framing.

Saying there are "very real risks from a mechanistic standpoint" without clearly stating these are theoretical, cell-culture and rodent-model concerns is misleading to a general audience. Mechanistic plausibility is not clinical evidence. Most pharmacologically active compounds look dangerous in some cell-culture model. The VEGF and angiogenesis concern for BPC-157 is legitimate to raise, but it requires the qualifier that no human oncology data exists to confirm this risk translates in vivo at the doses typically used. A 2022 paper by Gwyer et al. in Frontiers in Pharmacology specifically noted the absence of human safety trial data as the core gap in the literature, not confirmed harm. Bhatti would be on stronger ground saying "we do not know enough yet" rather than implying the risk is established. That said, he is right that almost nobody else in this content space is raising it at all, and raising an unanswered safety question is not the same as lying about it.

What should you actually know?

The peptide content ecosystem has a serious evidence problem, and Bhatti is one of the few creators pointing at it honestly, even if his framing occasionally outruns the data.

Here is what the evidence actually supports as of mid-2024. BPC-157 has shown wound healing, gut protective, and tendon repair effects in rodent models across dozens of studies. Human trials are essentially nonexistent. TB-500, specifically the synthetic fragment TB4-Frag, has reached Phase II trials for cardiac repair (RegeneRx, 2013) but not for the athletic recovery uses it is primarily marketed for. MK-677 is not a peptide but a ghrelin mimetic, and its long-term IGF-1 elevation carries metabolic and potentially oncologic considerations that are better characterized than BPC-157's risks. The Food and Drug Administration has flagged several of these compounds as unapproved drugs when sold for human use. Anyone using these compounds outside of a supervised clinical or research context is operating without a human safety net. That is the "appropriate context" Bhatti is referencing, and it is a legitimate point even when the risk certainty in his delivery is inflated.